Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00329914
Other study ID # predict2006
Secondary ID
Status Completed
Phase Phase 2
First received May 24, 2006
Last updated July 22, 2011
Start date June 2006
Est. completion date September 2010

Study information

Verified date February 2009
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority Denmark: The Danish National Committee on Biomedical Research EthicsDenmark: Danish Dataprotection AgencyDenmark: Danish Medicines Agency
Study type Interventional

Clinical Trial Summary

The purpose of the study is to determine whether a daily dose of 200 mg progesterone administered vaginally from 20-23 to 34 weeks' gestation will reduce the rate of preterm delivery amongst twin pregnancies.


Description:

Multiple gestations account for 2% of all pregnancies, but cause more than 10% of the cases of preterm delivery. Due to increasing maternal age and use of assisted reproduction the number of multiple gestations is larger than ever. If markers of preterm delivery can be identified and means of preventing preterm delivery are found, it will be possible to reduce the number of children admitted to hospital because of prematurity.

Recently, two larger randomised studies investigated the effect of progesterone in singleton pregnancies of women who had previously delivered preterm. They both found a significant reduction in the preterm delivery rate in the progesterone group compared to a placebo group.

The study will be performed as a randomized, double-blind placebo controlled study of twin pregnancies in Denmark and Austria. The women will be randomised in a 1:1 ratio to two groups (progesterone versus placebo). Randomisation will be stratified per centre and according to chorionicity, as the risk of preterm delivery is doubled in monochorionic twins compared to dichorionic twins.


Recruitment information / eligibility

Status Completed
Enrollment 677
Est. completion date September 2010
Est. primary completion date February 2009
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Twin pregnancy

- Informed consent

- 18-23 weeks' gestation

- Participants must be fluent in the language spoken in the respective centres

Exclusion Criteria:

- Age < 18 years

- Known allergy to progesterone or peanuts

- Active thromboembolic disorders or a history of hormone-associated thromboembolic disorders

- Rupture of membranes at the time of inclusion

- Monoamniotic twins

- Pregnancies treated for or with signs of twin-to-twin transfusion syndrome at inclusion

- Multiple pregnancies reduced to twin pregnancies

- Known significant structural or chromosomal fetal abnormality

- Chorionicity not assessed before 15 weeks

- Known or suspected malignancy in genitals or breasts

- Known liver disease

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Progesterone
Vaginal pessaries, 200 mg/day
Placebo
Placebo pessaries containing peanut oil

Locations

Country Name City State
Austria Graz University Hospital Graz
Austria Innsbruck University Hospital Innsbruck
Austria Klagenfurt Hospital Klagenfurt
Austria Vienna University Hospital Vienna
Denmark Aalborg Hospital Aalborg
Denmark Skejby Hospital Aarhus
Denmark Rigshospitalet Copenhagen
Denmark Glostrup Hospital Glostrup
Denmark Gentofte Hospital Hellerup
Denmark Herlev Hospital Herlev
Denmark Hilleroed Hospital Hilleroed
Denmark Holbaek Hospital Holbaek
Denmark Hvidovre Hospital Hvidovre
Denmark Odense University Hospital Odense
Denmark Roskilde Hospital Roskilde
Denmark Soenderborg Hospital Soenderborg
Denmark Viborg Hospital Viborg

Sponsors (4)

Lead Sponsor Collaborator
Rigshospitalet, Denmark AP Moeller Foundation, The Danish Medical Research Council, The Danish Medical Society in Copenhagen

Countries where clinical trial is conducted

Austria,  Denmark, 

References & Publications (2)

Klein K, Rode L, Nicolaides KH, Krampl-Bettelheim E, Tabor A; PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high-risk twin pregnancies: secondary analysis of a placebo-controlled randomized trial and meta-analysis. Ultraso — View Citation

Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A; PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obst — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of delivery < 34 weeks, in the study group versus the control group Participants will be followed until 3 weeks after delivery No
Secondary Physical and neurological development of the children at 6 and 18 months 2 years after delivery Yes
Secondary The relationship between cervical length and prophylactic progesterone treatment Participants will be followed until 3 weeks after delivery No
Secondary Determination of proteomics and RNA in preterm delivery and term delivery and an evaluation of the effect of progesterone on proteomics and RNA Participants will be followed until 3 weeks after delivery No
Secondary Assessment of the potential anti-inflammatory effect of progesterone by cytokine-measurements Participants will be followed until 3 weeks after delivery No
Secondary Assessment of the effect of progesterone on CRH-levels in twin pregnancies Participants will be followed until 3 weeks after delivery No
See also
  Status Clinical Trial Phase
Completed NCT03304782 - Fitbit Activity Tracker to Predict Risk of Preterm Birth
Recruiting NCT02420743 - Serum Ferritin Concentration and Fetal MCA Doppler as Predictors for Preterm Delivery
Completed NCT01665378 - Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes N/A
Completed NCT01119963 - Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM) Phase 2/Phase 3
Completed NCT00141908 - Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate Phase 2
Recruiting NCT05278130 - Serial Screening and Treatment of Bacterial Vaginosis Trial N/A
Terminated NCT03596125 - Correction of Neonatal Glutathione by N-acetylcysteine in Pregnant Women at Risk of Premature Birth (GSH MAP) Phase 2/Phase 3
Recruiting NCT03123926 - Spontaneous Preterm Birth Marker Test N/A
Completed NCT00201643 - A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome Phase 4
Completed NCT01353807 - Impact of Fish Oil Supplementation in 3rd Trimester of Pregnancy on Maternal and Offspring Health N/A
Terminated NCT02545127 - Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely Phase 2
Completed NCT02371356 - Comparing Effectiveness of Treating Depression With & Without Comorbidity to Improve Fetal Health
Active, not recruiting NCT01009723 - Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers N/A
Completed NCT00883324 - Comparison of Fetal Fibronectin (fFN) Specimen Collection Methodologies: With Speculum Versus Without Speculum N/A
Completed NCT00615550 - PREGNANT Short Cervix Trial Phase 3
Completed NCT02694679 - Randomized Controlled Trial of Social Network Targeting in Honduras N/A
Completed NCT01031017 - Prophylactic Administration of Natural Progesterone in the Prevention of Preterm Delivery in Twin Pregnancies Phase 4
Completed NCT00331695 - Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery Phase 4
Completed NCT01818518 - Neonatal Outcome by Reason for Delivery
Completed NCT04637880 - 25- Hydroxyvitamin D Levels in Pregnancy and Effects on Pregnancy Related Disorders

External Links